Substituted benzyl-pyrimidines targeting thymidine monophosphate kinase of Mycobacterium tuberculosis: Synthesis and in vitro anti-mycobacterial activity

Bioorganic and Medicinal Chemistry

Volumn 16, Issue 11, 2008, Pages 6075-6085

  Gasse, Cécile ^a   Douguet, Dominique ^b   Huteau, Valérie ^a   Marchal, Gilles ^a   Munier Lehmann, Hélène ^a   Pochet, Sylvie ^a  

^a INSTITUT PASTEUR   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

Benzyl pyrimidines; Inhibitors; Mycobacterium tuberculosis; Palladium catalyzed reaction; Thymidine monophosphate kinase

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 3 [4 (THYMIN 1 YLMETHYL)PHENYL]PROPIONAMIDE; 4 (5 BROMO 2,4 DIOXO 3,4 DIHYDRO 2H PYRIMIDIN 1 YLMETHYL)BUTANOIC ACID; 4 (5 BROMOO 2,4 DIOXO 3,4 DIHYDRO 2H PYRIMIDIN 1 YLMETHYL)BUTANAMIDE; 4 (5 CHLORO 2,4 DIOXO 3,4 DIHYDRO 2H PYRIMIDIN 1 YLMETHYL)BUTANAMIDE; 5 [5 CHLORO 4 (2,4 DIOXO 3,4 DIHYDRO 2H PYRIMIDIN 1 YLMETHYL)PHENYL]BUTANOIC ACID; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; ALKYL GROUP; FUNCTIONAL GROUP; PHOSPHOTRANSFERASE; THYMIDINE PHOSPHATE; THYMIDYLATE KINASE;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM CULTURE; DRUG DESIGN; DRUG SYNTHESIS; ENZYME INHIBITION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTITUBERCULAR AGENTS; CERCOPITHECUS AETHIOPS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NUCLEOSIDE-PHOSPHATE KINASE; PYRIMIDINES; VERO CELLS;

CORYNEBACTERINEAE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS;

EID: 44449114750     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2008.04.045     Document Type: Article

References (37)

1. Global alliance for TB Drug Development: Preparing the World for Rapid Uptake a Faster, Better TB cure (http://www.tballiance.org/newscenter/publications.php) 07/13/2007.
2. World Health Organization (http://www.who.org), 2006.
3. Ballell L., Field R.A., Duncan K., and Young R.J. Antimicrob. Agents Chemother. 49 (2005) 2153
4. Van Daele I., and van Calenbergh S. Expert Opin. Ther. Patents 15 (2005) 131
5. Tomioka H. Curr. Pharm. Des. 12 (2006) 4047
6. Janin Y.L. Bioorg. Med. Chem. 15 (2007) 2479
7. Braendvang M., and Gundersen L.L. Bioorg. Med. Chem. 15 (2007) 7144
8. Parker W.B., and Long M.C. Curr. Pharm. Des. 13 (2007) 599
9. Zhang Y., Post-Martens K., and Denkin S. Drug Discovery Today 11 (2006) 21
10. Sacchettini J.C., Rubin E.J., and Freundlich J.S. Nat. Rev. Microbiol. 6 (2008) 41
11. Andries K., Verhasselt P., Guillemont J., Gohlmann H.W., Neefs J.M., Winkler H., Van Gestel J., Timmerman P., Zhu M., Lee E., Williams P., de Chaffoy D., Huitric E., Hoffner S., Cambau E., Truffot-Pernot C., Lounis N., and Jarlier V. Science 307 (2005) 223
12. Stover C.K., Warrener P., VanDevanter D.R., Sherman D.R., Arain T.M., Langhorne M.H., Anderson S.W., Towell J.A., Yuan Y., McMurray D.N., Kreiswirth B.N., Barry C.E., and Baker W.R. Nature 405 (2000) 962
13. Cole S.T., Brosch R., Parkhill J., Garnier T., Churcher C., Harris D., Gordon S.V., Eiglmeier K., Gas S., Barry III C.E., Tekaia F., Badcock K., Basham D., Brown D., Chillingworth T., Connor R., Davies R., Devlin K., Feltwell T., Gentles S., Hamlin N., Holroyd S., Hornsby T., Jagels K., and Barrell B.G. Nature 393 (1998) 537
14. Lamichhane G., Zignol M., Blades N.J., Geiman D.E., Dougherty A., Grosset J., Broman K.W., and Bishai W.R. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 7213
15. Long M.C., and Parker W.B. Biochem. Pharmacol. 71 (2006) 1671
16. Williams K.J., and Duncan K. Curr. Mol. Med. 7 (2007) 297
17. Barker J.J. Drug Discovery Today 11 (2006) 391
18. Sassetti C.M., Boyd D.H., and Rubin E.J. Mol. Microbiol. 48 (2003) 77
19. Munier-Lehmann H., Chaffotte A., Pochet S., and Labesse G. Protein Sci. 10 (2001) 1195
20. Pochet S., Dugué L., Douguet D., Labesse G., and Munier-Lehmann H. ChemBioChem 3 (2002) 108
21. Vanheusden V., Munier-Lehmann H., Pochet S., Herdewijn P., and Van Calenbergh S. Bioorg. Med. Chem. Lett. 12 (2002) 2695
22. Vanheusden V., Munier-Lehmann H., Froeyen M., Dugué L., Heyerick A., De Keukeleire D., Pochet S., Busson R., Herdewijn P., and Van Calenbergh S. J. Med. Chem. 46 (2003) 3811
23. Vanheusden V., Van Rompaey P., Munier-Lehmann H., Pochet S., Herdewijn P., and Van Calenbergh S. Bioorg. Med. Chem. Lett. 13 (2003) 3045
24. Vanheusden V., Munier-Lehmann H., Froeyen M., Busson R., Rozenski J., Herdewijn P., and Van Calenbergh S. J. Med. Chem. 47 (2004) 6187
25. Pochet S., Dugué L., Labesse G., Delepierre M., and Munier-Lehmann H. ChemBioChem 4 (2003) 742
26. Van Daele I., Munier-Lehmann H., Hendrickx P.M., Marchal G., Chavarot P., Froeyen M., Qing L., Martins J.C., and Van Calenbergh S. ChemMedChem 1 (2006) 1081
27. Li de la Sierra I., Munier-Lehmann H., Gilles A.M., Barzu O., and Delarue M. J. Mol. Biol. 311 (2001) 87
28. Douguet D., Munier-Lehmann H., Labesse G., and Pochet S. J. Med. Chem. 48 (2005) 2457
29. Munier-Lehmann, H., Douguet, D., Labesse, G., Pochet, S. New aryl pyrimidyl compounds, pharmaceutical compositions comprising them, their use as antimycrobial agents, PCT, 2006.
30. Part of this work was presented during the XVIIth Round Table for 'Nucleosides, Nucleotides and Nucleic Acids' in September 2006. Gasse C., Huteau V., Douguet D., Munier-Lehmann H., and Pochet S. Nucleosides Nucleotides Nucleic Acids 26 (2007) 1057
31. Cruickshank K.A., Jiricny J., and Reese C.B. Tetrahedron Lett. 25 (1984) 681
32. Heck R.F. Acc. Chem. Res. 12 (1979) 146
33. Sonogashira K., Tohda Y., and Hagihara N. Tetrahedron Lett. (1975) 4467
34. Butterfield K., and Thomas E.J. J. Chem. Soc., Perkin Trans. 1 (1998) 737
35. Kumar R., Wiebe L.I., and Knaus E.E. Can. J. Chem. 72 (1994) 2005
36. Palomino J.C., Martin A., Camacho M., Guerrra H., Swings J., and Portaels F. Antimicrob. Agents Chemother. 46 (2002) 2720
37. Van Daele I., Munier-Lehmann H., Froeyen M., Balzarini J., and Van Calenbergh S. J. Med. Chem. 50 (2007) 5281